Here Are Friday’s Biggest Calls on Wall Street

UBS Reiterates Nvidia as Buy

UBS maintained its Buy rating on Nvidia (NVDA), citing September Taiwan export data as evidence of strong AI demand.

The firm said elevated export levels remain consistent with healthy underlying demand driven by AI.

Rothschild & Co Redburn Reiterates Apple as Buy

Rothschild & Co Redburn maintained its Buy rating on Apple (AAPL), while highlighting the need for the company’s AI strategy to deliver more compelling results by 2027.

The firm said Meta’s Muse assistant is unlikely to replace smartphones but serves as a reminder that Apple’s fast-follower approach to AI must impress investors.

Yorkville Ives Initiates Tesla as Outperform

Yorkville Ives initiated coverage of Tesla (TSLA) with an Outperform rating, describing the company as being in the early stages of its growth opportunity.

The firm views Tesla as one of the clearest ways to gain exposure to physical AI in public markets.

Barclays Initiates SpaceX as Overweight

Barclays initiated coverage of SpaceX (SPCX) with an Overweight rating and a $254 12-month price target, citing strong execution and significant upside potential.

Baird Upgrades Humana to Outperform from Neutral

Baird upgraded Humana (HUM) to Outperform from Neutral and raised its price target to $596.

The firm expressed greater confidence in the company’s ability to generate more than $35 in adjusted EPS in 2028.

Barclays Initiates Boeing as Overweight

Barclays initiated coverage of Boeing (BA) with an Overweight rating, saying the stock’s current valuation offers an attractive entry point.

The firm set a $300 price target.

BMO Initiates American Express as Outperform

BMO initiated coverage of American Express (AXP) with an Outperform rating, citing the company’s potential for sustained premium growth.

The firm believes concerns about competition in premium cards and elevated reinvestment overlook the continued expansion of American Express’s premium ecosystem.

Wolfe Initiates GSK as Outperform

Wolfe initiated coverage of GSK (GSK) with an Outperform rating and a $70 price target, citing potential upside drivers for the pharmaceutical company.

Oppenheimer Upgrades Fastly to Outperform from Perform

Oppenheimer upgraded Fastly (FSLY) to Outperform and set a $35 price target.

The firm cited positive industry checks indicating growing contract values, increased adoption of newer security products, and early monetization of agentic AI traffic.